Candriam S.C.A. Has $27.71 Million Stake in Xenon Pharmaceuticals Inc. $XENE

Candriam S.C.A. raised its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 14.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 476,494 shares of the biopharmaceutical company’s stock after purchasing an additional 59,092 shares during the quarter. Candriam S.C.A.’s holdings in Xenon Pharmaceuticals were worth $27,708,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Danske Bank A S purchased a new position in shares of Xenon Pharmaceuticals during the third quarter valued at approximately $32,000. Blue Trust Inc. grew its stake in shares of Xenon Pharmaceuticals by 2,560.7% in the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 717 shares in the last quarter. Kestra Advisory Services LLC bought a new stake in shares of Xenon Pharmaceuticals in the 4th quarter worth $33,000. Osaic Holdings Inc. raised its holdings in shares of Xenon Pharmaceuticals by 541.4% in the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,034 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Xenon Pharmaceuticals in the fourth quarter valued at about $43,000. Institutional investors own 95.45% of the company’s stock.

Insider Activity

In related news, Director Gillian Cannon sold 1,190 shares of the business’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the sale, the director directly owned 1,455 shares in the company, valued at approximately $77,318.70. The trade was a 44.99% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Gary Patou sold 1,322 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the sale, the director directly owned 24,896 shares in the company, valued at approximately $1,322,973.44. This trade represents a 5.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 4.07% of the company’s stock.

Xenon Pharmaceuticals Stock Down 2.9%

Xenon Pharmaceuticals stock traded down $2.04 during trading on Friday, hitting $68.92. The stock had a trading volume of 1,535,878 shares, compared to its average volume of 1,830,298. Xenon Pharmaceuticals Inc. has a 1 year low of $30.00 and a 1 year high of $72.66. The stock’s 50 day moving average is $56.18 and its two-hundred day moving average is $51.08. The stock has a market cap of $6.66 billion, a price-to-earnings ratio of -14.66 and a beta of 0.61.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.17). During the same period in the previous year, the company earned ($0.83) earnings per share. As a group, equities research analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.92 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on XENE shares. Wedbush cut their price target on shares of Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating on the stock in a report on Monday, March 16th. Royal Bank Of Canada boosted their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $69.00 target price on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. Needham & Company LLC decreased their price target on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Finally, JPMorgan Chase & Co. boosted their price objective on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 27th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $77.20.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.